Valerie S. Kitchen was recently appointed Vice President, Clinical Biomarkers at Bristol-Myers Squibb Company in Princeton, New Jersey. She previously held the position of Vice President, Clinical Pharmacology, Modeling and Simulation when she started with BMS in March 2009. Dr. Kitchen has broad industry and clinical experience and joined Bristol-Myers Squibb from GlaxoSmithKline (GSK) where she had spent 8 yrs working in translational medicine and clinical pharmacology across a number of different therapeutic areas. Valerie started her career in industry at SmithKline Beecham in 1999, as Associate Director of their UK-based Clinical Pharmacology Unit, advanced to Director, Clinical Pharmacology and Discovery Medicine (CPDM) in the merged GSK, was promoted to Vice President, CDPM, Musculoskeletal, Microbial and Proliferative Diseases CEDD (Center of Excellence for Drug Discovery) and then Vice President, CPDM in the Infectious Disease CEDD. Prior to her transition to industry, Valerie was a Senior Lecturer (Associate Professor) at St. Mary’s Hospital / Imperial College in London where she was responsible for the HIV clinical trials unit, overseeing the execution of phase I/II studies and the conduct of anti-retroviral research, including the establishment of clinical research sites in Uganda. She has served on multiple Medical Research Council and World Health Organization committees related to HIV infection. She was awarded several MRC and EU research grants as an academic and is widely published. Valerie has an MB, ChB from the University of Leicester Medical School, trained as an infectious diseases physician in London and in 1996 was awarded Fellowship of the Royal College of Physicians.